RxDoctor Payments Data

Mark Brinkman, DO

Family Medicine · Callahan, FLNPI 1245764133

Payments from drug & device makers

$6,569in general payments, 2019–2025

Across 336 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Pfizer$601
  • Lilly USA, LLC$597
  • Novo Nordisk$518
  • Bayer$477
  • Edwards Lifesciences$460
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$6,46098%
  • Education$501%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,569 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$94,947
Medicare patients
275
Services billed
1,491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$74,234
EliquisApixaban56$50,604
MounjaroTirzepatide42$48,670
JardianceEmpagliflozin45$35,234
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$27,673
EntrestoSacubitril/Valsartan17$17,162
MyrbetriqMirabegron13$16,927
JanuviaSitagliptin Phosphate16$12,011
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$11,546
FarxigaDapagliflozin Propanediol14$10,505
XareltoRivaroxaban11$9,185
Soliqua 100-33Insulin Glargine/Lixisenatide18$8,798
Breo ElliptaFluticasone/Vilanterol15$8,614
MovantikNaloxegol Oxalate14$5,863
Albuterol Sulfate HfaAlbuterol Sulfate133$2,860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$518$74,23437 claims
PfizerEliquis$601$50,60456 claims
Lilly USA, LLCMounjaro$597$48,67042 claims
GSKTrelegy Ellipta, Breo Ellipta$196$36,28740 claims
Boehringer IngelheimJardiance$325$35,23445 claims
NovartisEntresto$33$17,16217 claims
Astellas Pharma US IncMyrbetriq$135$16,92713 claims
AstraZenecaFarxiga, Symbicort$1,018$13,11225 claims
MerckJanuvia$181$12,01116 claims
Johnson & JohnsonXarelto$47$9,18511 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$122$8,79818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Callahan

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →